Download PDF
Horm Metab Res 2024; 56(06): 419-423
DOI: 10.1055/a-2210-3395
Original Article: Endocrine Care

Risk Factors Analysis of Severe Liver Injury Induced by Statins

Feng-yun Su
1   Department of Pharmacy, The Second Affiliated Hospital of Shandong First Medical University, Tai’an, China
,
Wen-hua Li
2   Department of Orthopedics, The Second Affiliated Hospital of Shandong First Medical University, Tai’an, China
,
Xu-dong Zhao
3   Department of Obstetrics and Gynecology, The Affiliated Tai’an City Central Hospital of Qingdao University, Qingdao, China
,
Qian Han
4   Department of Respiratory, The Second Affiliated Hospital of Shandong First Medical University, Tai’an, China
,
Xin Xu
5   Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University, Tai’an, China
,
Tao Geng
1   Department of Pharmacy, The Second Affiliated Hospital of Shandong First Medical University, Tai’an, China
› Author Affiliations Funding Information Shandong Adverse Drug Reaction Monitoring Center Project — 2017SDADRKY05
› Further Information
Also available at
    Permissions and Reprints

Abstract

The aim of this study is to report the risk factors of severe statin induced liver injury (SILI). From the database of Shandong ADR Monitoring Center and Outpatients and inpatients in our hospital, SILI cases reported from 2013 to 2021 were extracted and screened. The diagnostic criteria of SILI, the inclusion and exclusion criteria of severe and general SILI were established separately. After the SILI cases were selected and confirmed, the socio-demographic and clinical characteristics were collected. Single factor chi-square test and multi-factor unconditional logistic regression analysis were used to analyze the influencing factors of severe SILI. From 1391 reported cases, 1211 met SILI diagnostic criteria, of which 157 were severe SILI and 964 were general SILI. Univariate analysis showed that age, drug combination, statin category were the influencing factors of severe SILI (p<0.1). Multivariate logistic analysis showed that drug combination and statin category were the influencing factors of severe SILI (p<0.05). Atorvastatin caused the most serious SILI, and its risk is 1.77 times higher than rosuvastatin. The serious SILI risk of drug combination was 2.08 times higher than statin alone. The patient with these factors should be monitored intensively during clinical treatment, to ensure their medication safety.

Key words

statin induced liver injury - severity - influence factors


Publication History

Received: 04 August 2023

Accepted after revision: 13 November 2023

Accepted Manuscript online:
13 November 2023

Article published online:
03 January 2024

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Opoku S, Gan Y, Yobo EA. et al. Awareness, treatment, control, and determinants of dyslipidemia among adults in China. Sci Rep 2021; 11: 10056
    CrossrefPubMedGoogle Scholar
  • 2 Huang Y, Gao L, Xie X. et al Epidemiology of dyslipidemia in Chinese adults: meta-analysis of prevalence, awareness, treatment, and control. Popul Health Metr 2014; 12 Article No. 28
    PubMedGoogle Scholar
  • 3 Collins R, Reith C, Emberson J. et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388: 2532-2561
    CrossrefPubMedGoogle Scholar
  • 4 Working Group of the Evaluation on the Safety of S. [Experts consensus of the evaluation on the statin drugs safty]. Zhonghua Xin Xue Guan Bing Za Zhi 2014; 42: 890-894
    PubMedGoogle Scholar
  • 5 Bays H, Cohen DE, Chalasani N. et al. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol 2014; 8: S47-S57
    PubMedGoogle Scholar
  • 6 Yu Y-C, Mao Y-M, Chen C-W. et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int 2017; 11: 221-241
    CrossrefPubMedGoogle Scholar
  • 7 Shen T, Liu Y, Shang J. et al. Incidence and etiology of drug-induced liver injury in mainland China. Gastroenterology 2019; 156: 2230-2241 e11
    CrossrefPubMedGoogle Scholar
  • 8 Li C-P, Song Y-X, Lin Z-J. et al Essential trace elements in patients with dyslipidemia: A meta-analysis. Curr Med Chem 2023; DOI: 10.2174/0929867330666230428161653. Online ahead of print
    CrossrefPubMedGoogle Scholar
  • 9 Wang YR, Pan R, He L. Taking medication for diabetes may modify the link between serum zinc concentrations and prediabetes and diabetes in the general population. Biol Trace Elem Res 2023; 201: 1118-1119
    CrossrefPubMedGoogle Scholar
  • 10 Song YX, He LP, Li CP. The relationship between serum calcium level and risk factor of pregnancy-induced hypertension: a meta-analysis. Clin Exp Obstet Gynecol 2023; 50: 66
    CrossrefPubMedGoogle Scholar
  • 11 Li XY, Zhong W, Mao Ym. [Statin-related drug-induced liver injury]. Zhonghua Gan Zang Bing Za Zhi 2023; 31: 659-663
    PubMedGoogle Scholar
  • 12 Averbukh LD, Turshudzhyab A, Wu DC. et al. Statin-induced liver injury patterns: a clinical review. J Clin Transl Hepatol 2022; 10: 543-552
    CrossrefPubMedGoogle Scholar
  • 13 Yu J-M, Chen W-M, Shia B-C. et al. Protective effects of different classes, intensity, cumulative dose-dependent of statins against primary ischemic stroke in patients with type 2 diabetes mellitus. Curr Atheroscler Rep 2023; 25: 619-628
    CrossrefPubMedGoogle Scholar
  • 14 Huang P-H, Lu Y-A, Tsai Y-L. et al. 2022 Taiwan lipid guidelines for primary prevention. J Formos Med Assoc 2022; 121: 2393-2407
    CrossrefPubMedGoogle Scholar
  • 15 Sniderman AD. Is there value in liver function test and creatine phosphokinase monitoring with statin use?. Am J Cardiol 2004; 94: 30F-34F
    CrossrefPubMedGoogle Scholar
  • 16 Tsui L, Chen L, Ye P. et al. Adverse drug reactions of non-statin antihyperlipidaemic drugs in China from 1989 to 2019: a national database analysis. BMJ Open 2023; 13: e068915
    CrossrefPubMedGoogle Scholar
  • 17 Charles EC, Olson KL, Sandhoff BG. et al. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med 2005; 118: 618-624
    CrossrefPubMedGoogle Scholar
  • 18 Bjornsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol 2012; 56: 374-380
    CrossrefPubMedGoogle Scholar
  • 19 He LP, Zhou ZX, Li CP. Narrative review of ferroptosis in obesity. J Cell Mol Med 2023; 27: 920-926
    CrossrefPubMedGoogle Scholar
  • 20 Li CP, Su HQ, He LP. Vitamin D may alleviate pre-eclampsia by modulating the ferroptosis signalling pathway: a hypothesis based on recent literature. J Cell Mol Med 2023; 27: 1923-1927
    CrossrefPubMedGoogle Scholar
  • 21 Yu XL, Li CP, He LP. Vitamin D may alleviate irritable bowel syndrome by modulating serotonin synthesis: a hypothesis based on recent literature. Front Physiol 2023; 14: 1152958
    CrossrefPubMedGoogle Scholar
  • 22 Yu X-L, Wu Q-Q, He LP. et al. Role of in vitamin D in irritable bowel syndrome. World J Clin Cases 2023; 11: 2677-2683
    CrossrefPubMedGoogle Scholar